7-150952481-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000238.4(KCNH2):c.1501G>A(p.Asp501Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 14/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D501H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000238.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
KCNH2 | NM_000238.4 | c.1501G>A | p.Asp501Asn | missense_variant | 6/15 | ENST00000262186.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
KCNH2 | ENST00000262186.10 | c.1501G>A | p.Asp501Asn | missense_variant | 6/15 | 1 | NM_000238.4 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 33
GnomAD4 exome Cov.: 40
GnomAD4 genome ? Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 22, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies suggest a damaging effect where p.(D501N) resulted in a 50% reduction in protein trafficking (Sadrieh et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25820318, 12402336, 18441445, 19716085, 19352046, 17088455, 26669661, 20486126, 21185501, 29358271, 14998624, 25254353, 25576780, 32383558, 34546463, 30530868, 31737537, 28794082) - |
Long QT syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Feb 16, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 501 of the KCNH2 protein (p.Asp501Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with long QT syndrome (PMID: 12402336, 14998624, 17088455, 25254353). ClinVar contains an entry for this variant (Variation ID: 67208). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects KCNH2 function (PMID: 25254353). This variant disrupts the p.Asp501 amino acid residue in KCNH2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16414944, 19926013). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 13, 2017 | The p.D501N variant (also known as c.1501G>A), located in coding exon 6 of the KCNH2 gene, results from a G to A substitution at nucleotide position 1501. The aspartic acid at codon 501 is replaced by asparagine, an amino acid with highly similar properties, and is located in S3 transmembrane helix. This alteration has been reported in multiple long QT syndrome (LQTS) cohorts (Jongbloed R et al. Hum. Mutat., 2002 Nov;20:382-91; Lupoglazoff JM et al. J. Am. Coll. Cardiol., 2004 Mar;43:826-30; Tan HL et al. Circulation, 2006 Nov;114:2096-103; Nagaoka I et al. Circ. J., 2008 May;72:694-9; Kapplinger JD et al. Heart Rhythm, 2009 Sep;6:1297-303; Pundi KN et al. Heart Rhythm, 2015 Apr;12:776-81). It has also been identified in a subject with a prolonged QT interval and features of left ventricular non-compaction (Ogawa K et al. Circ. J., 2009 Nov;73:2169-72). One study suggested this variant may cause a reduction in protein trafficking (Sadrieh A et al. Nat Commun., 2014 Sept;5:5069). In addition, other alterations affecting the same amino acid, p.D501H (c.1501G>C) and p.D501G (c.1502A>G) have been reported in association with LQTS (Napolitano C et al. JAMA, 2005 Dec;294:2975-80; Shimizu W et al. J. Am. Coll. Cardiol., 2009 Nov;54:2052-62). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Congenital long QT syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Long QT syndrome in the following publications (PMID:12402336;PMID:14998624;PMID:18441445;PMID:19716085). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at